Profile data is unavailable for this security.
About the company
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
- Revenue in USD (TTM)54.85m
- Net income in USD-47.06m
- Incorporated2005
- Employees217.00
- LocationBiodesix IncSuite 100, 2970 Wilderness PlaceBOULDER 80301United StatesUSA
- Phone+1 (303) 417-0500
- Fax+1 (303) 417-9700
- Websitehttps://www.biodesix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Oncology Network Inc | 1.34bn | -15.48m | 86.78m | 1.53k | -- | -- | -- | 0.0648 | -2.07 | -2.07 | 161.04 | -9.94 | 3.53 | 33.53 | 9.26 | 878,552.80 | -22.82 | -- | -78.96 | -- | 5.00 | -- | -6.46 | -- | 1.20 | -7.84 | 0.606 | -- | 11.27 | -- | -- | -- | -- | -- |
| Cardiff Lexington Corp | 12.35m | -2.15m | 94.39m | 2.00 | -- | -- | -- | 7.64 | -1,023.97 | -1,089.87 | 65.54 | 0.0058 | 0.7163 | -- | 1.32 | 6,173,760.00 | -8.97 | -52.27 | -23.24 | -- | 70.08 | 57.44 | -12.53 | -58.31 | -- | 1.13 | 0.4002 | -- | 21.45 | 49.15 | -1,701.81 | -- | -- | -- |
| ProPhase Labs Inc | 28.72m | -23.60m | 97.68m | 113.00 | -- | 2.06 | -- | 3.40 | -1.34 | -1.34 | 1.64 | 2.49 | 0.3098 | 5.81 | 0.7872 | 254,115.00 | -25.45 | 0.9106 | -33.00 | 1.12 | 18.41 | 50.32 | -82.18 | 0.9325 | 1.73 | -20.42 | 0.1953 | 665.78 | -63.81 | 27.59 | -190.90 | -- | 86.46 | -- |
| Longduoduo Co Ltd | 8.78m | 1.77m | 155.13m | -- | 87.54 | 389.74 | 74.86 | 17.67 | 0.0591 | 0.0591 | 0.2923 | 0.0133 | 5.06 | 453.60 | 134.94 | -- | 114.14 | -- | -- | -- | 95.04 | -- | 22.55 | -- | 1.04 | -- | 0.00 | -- | 17.93 | -- | 99.48 | -- | -- | -- |
| DLH Holdings Corp | 402.59m | 3.07m | 157.27m | 3.20k | 56.08 | 1.47 | 7.78 | 0.3907 | 0.197 | 0.197 | 27.68 | 7.50 | 1.17 | -- | 6.57 | 125,807.80 | 0.8924 | 5.38 | 1.11 | 7.20 | 20.92 | 20.56 | 0.7631 | 3.41 | -- | 1.50 | 0.6069 | 0.00 | -4.88 | 23.05 | -93.73 | -28.16 | -0.903 | -- |
| Biodesix Inc | 54.85m | -47.06m | 166.29m | 217.00 | -- | -- | -- | 3.03 | -0.5465 | -0.5465 | 0.6308 | -0.0566 | 0.653 | -- | 7.42 | 252,760.40 | -56.02 | -55.60 | -82.08 | -80.94 | 76.27 | 59.53 | -85.80 | -105.15 | -- | -3.71 | 1.18 | -- | 28.46 | 19.16 | 20.32 | -- | 106.31 | -- |
| Joint Corp | 119.12m | -11.13m | 238.53m | 444.00 | -- | 9.09 | -- | 2.00 | -0.7556 | -0.7556 | 8.04 | 1.75 | 1.29 | -- | 35.08 | 268,283.10 | -12.01 | 4.32 | -17.55 | 6.05 | 90.94 | 90.28 | -9.34 | 3.68 | -- | 1,198.66 | 0.0022 | -- | 16.24 | 26.27 | -1,656.09 | -- | 35.09 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 09 Apr 2024 | 6.67m | 5.83% |
| AIGH Capital Management LLCas of 31 Mar 2024 | 3.32m | 2.90% |
| Birchview Capital LPas of 23 May 2024 | 2.66m | 2.32% |
| Telemark Asset Management LLCas of 31 Mar 2024 | 1.33m | 1.16% |
| Essex Investment Management Co. LLCas of 31 Mar 2024 | 925.61k | 0.81% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 892.91k | 0.78% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 786.84k | 0.69% |
| Opaleye Management, Inc.as of 31 Mar 2024 | 534.66k | 0.47% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 398.51k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 385.15k | 0.34% |
